Volver a Agenda
Session Chair(s)
Janet Jenkins-Showalter
Head, US Regulatory Policy
Genentech, A Member of the Roche Group, United States
Learning Objective : Identify a regulatory development strategy for diagnostically selected populations; Recognize approaches to defining the diagnostically selected population; Formulate strategies for multi-marker diagnostic development.
Speaker(s)
Panelist
Jeff Allen, PHD
Friends of Cancer Research, United States
President and Chief Executive Officer
Panelist
Erling Thor Donnelly, PHD
Pfizer Inc , United States
Team Leader, Dacomitinib and Palbociclib, Oncology
Panelist
Shayesteh Fürst-Ladani, MBA, MS
SFL Regulatory Affairs & Scientific Communication, Switzerland
CEO
¿Tiene una cuenta?